Timing clarification: Universal Health Services is scheduled to release second-quarter results after the market closes today, Monday, July 27, 2026. The earnings call is tomorrow, Tuesday, July 28, at 9:00 a.m. ET. (ir.uhs.com)
This report is less about whether UHS beats quarterly EPS and more about what the beat or miss is made of. Medicaid supplemental payments—particularly Florida—could materially lift reported results, while the deterioration in health-insurance-exchange coverage could create a meaningful offset through higher uninsured volumes and bad debt.
The key questions are:
Given the stock’s decline and low valuation, expectations appear subdued. But investors will probably discount a headline beat if it comes primarily from retroactive Medicaid payments without evidence that underlying volumes, margins and payer mix are stabilizing.
Published estimates vary by provider, reflecting uncertainty around supplemental-payment timing. A reasonable Street range is approximately:
| Metric | Q2 expectation | Q2 2025 |
|---|---|---|
| Revenue | $4.5B–$4.6B | $4.284B |
| Adjusted EPS | $5.65–$6.00 | $5.35 |
| Adjusted EBITDA net of NCI | Low-$630Ms | $642.9M |
Recent published estimates include approximately $5.66–$5.98 of EPS and $4.52–$4.60 billion of revenue, depending on the data source. (tickerleague.com)
UHS entered the quarter with full-year guidance of:
First-quarter adjusted EBITDA was $648.3 million and adjusted EPS was $5.62. Revenue grew 9.6%, but the quarter included significant supplemental-payment benefits and relatively weak underlying volumes. (ir.uhs.com)
UHS originally estimated a $75 million pretax full-year impact from the expiration of enhanced exchange subsidies. In Q1, it estimated approximately $15 million of impact. Exchange-related adjusted admissions declined about 5%, although management reserved as if the effective coverage reduction were in the low double digits because some patients might later fail to pay their premiums.
Management expected the problem to worsen through the year, ultimately assuming a roughly 25%–30% reduction in exchange coverage.
That forecast now looks like the central risk to guidance. HCA’s recent Q2 update showed:
UHS’s geographic and patient mix differs from HCA’s, so the magnitude should not be extrapolated directly. Nevertheless, the direction is concerning.
A modest revision would be manageable. A large increase could consume much of the Florida supplemental-payment upside.
Florida is the most likely source of upside.
On the Q1 call, UHS said it expected approximately $50 million of benefit from the pending Florida program and indicated that the final amount could be “measurably higher.” It planned to recognize the benefit when approval was received and revise guidance accordingly.
HCA has since confirmed that CMS approved Florida’s directed-payment program during Q2. HCA recognized approximately $400 million of incremental net benefit from Medicaid supplemental-payment programs, primarily Florida. (investor.hcahealthcare.com)
That strongly suggests UHS may recognize a Florida benefit in Q2, although its amount will depend on UHS’s eligible operations, provider-tax obligations and applicable periods.
Investors should separate:
A large headline beat accompanied by weak core EBITDA growth would be lower quality than a smaller beat supported by volume and margin improvement.
First-quarter consolidated results were solid on the surface:
But management acknowledged that core growth, excluding supplemental-payment effects and other moving pieces, had not yet reached the roughly 5% level embedded in full-year guidance.
Q1 same-facility acute-care results included:
Management attributed roughly 200 basis points of volume pressure to mild flu activity, respiratory trends and weather. March was described as more normal, which creates an expectation for better Q2 volumes.
However, the comparison is not easy: Q2 2025 acute adjusted admissions grew 2.0%. Furthermore, HCA reported healthy admissions and ER growth in Q2 but declining inpatient and outpatient surgeries, indicating that service mix may have been less favorable despite positive aggregate demand. (investor.hcahealthcare.com)
A good outcome: low-single-digit adjusted-admission growth with stable or improving labor efficiency.
A weaker outcome: positive admissions but soft surgery and acuity mix, leaving core EBITDA growth below revenue growth.
Q1 same-facility behavioral results included:
Demand remains strong, but growth continues to be constrained by staffing and a shift toward outpatient care. Management previously targeted roughly 2%–3% behavioral volume growth, making Q2 patient days and outpatient revenue important indicators.
The behavioral business should be capable of solid operating leverage if volume approaches the targeted range and wage inflation moderates.
UHS managed acute-care expenses well in Q1:
Behavioral labor remained more challenging. Salary and benefit expense per adjusted patient day increased approximately 6%, although that was an improvement from the 7%–8% increases experienced during 2025. Management expected further moderation as 2026 progressed.
The most constructive signal would be behavioral salary growth moving toward the mid-single digits while patient-day growth improves. Conversely, continued 6%–plus labor growth with sub-2% volumes would make meaningful margin expansion difficult.
Management expected earnings to accelerate through the year as new capacity opened and recent hospitals matured. Projects include:
Cedar Hill and the new Florida hospital were expected to be roughly earnings-neutral in aggregate for 2026: Florida would initially generate start-up losses, offset by improvement at Cedar Hill. In Q1, however, management said Cedar Hill’s recovery had become somewhat more back-end-loaded.
Investors should look for:
If Cedar Hill improves against last year’s start-up losses, it should provide a favorable comparison even before becoming fully mature.
A guidance increase is plausible because the original outlook did not include the potential Florida benefit. But exchange losses could absorb some or all of that upside.
| Scenario | Likely guidance response |
|---|---|
| Florida benefit is large; exchange pressure remains near plan | Raise EBITDA and EPS guidance |
| Florida benefit is large; exchange pressure also worsens | Maintain or modestly raise guidance |
| Florida largely offsets an exchange revision | Headline raise, but little change to underlying outlook |
| Exchange losses materially exceed Florida and core growth stays soft | Reduce or narrow guidance downward |
The most useful disclosure would be a bridge separating:
Without that bridge, a guidance increase may be difficult to interpret.
The proposed Talkspace acquisition remains strategically important. Talkspace shareholders approved the transaction on May 29, with approximately 73.5% of outstanding shares voting in favor. The transaction was originally expected to close during Q3 2026. (sec.gov)
UHS expects:
The earnings call should clarify:
UHS arranged a $400 million delayed-draw term loan in April specifically to fund the acquisition. It subsequently added a separate $700 million, 364-day delayed-draw facility for general corporate purposes and potential debt refinancing. (sec.gov)
Despite the acquisition, management had indicated that share repurchases remained a priority. UHS bought back 675,000 shares for $127 million in Q1 at an average price near $189 and had approximately $1.3 billion of authorization remaining.
With the stock recently below that Q1 repurchase price, investors will want to know whether buyback activity accelerated.
UHS closed July 24 at approximately $155.78, down roughly:
At that price, the stock trades at approximately 6.6 times the midpoint of 2026 adjusted EPS guidance.
That is a low headline multiple, but the discount reflects several legitimate concerns:
The low valuation creates room for upside if management can demonstrate that exchange pressure is contained and core earnings are improving. It does not, however, eliminate the risk of another guidance reset.
| Indicator | Constructive | Concerning |
|---|---|---|
| Exchange headwind | Full-year estimate stays near $75M | Material increase; sharp uninsured-volume growth |
| Florida payment | Benefit above $50M with recurring component | Mostly retroactive and consumed by bad debt |
| Acute volume | Adjusted admissions +2% or better | Flat/negative volume or weak surgery mix |
| Behavioral volume | Patient days near +2%–3% | Below 2% despite staffing investments |
| Behavioral labor | Wage growth moderates toward mid-single digits | Remains 6%–plus without operating leverage |
| Core EBITDA | Clear acceleration versus Q1 | Growth relies primarily on supplemental payments |
| Guidance | Raised for both Florida and stronger operations | Maintained only because Florida offsets exchange losses |
| Talkspace | Q3 close reaffirmed; accretion quantified | Delay, higher costs or reduced buybacks |
| Cash flow | Strong collections and stable DSO | Rising receivables or bad-debt reserves |
The most likely outcome is a noisy quarter in which Florida Medicaid payments support reported earnings, while management increases its estimate of exchange-related pressure. The stock reaction will depend on which change is larger and, more importantly, whether underlying hospital EBITDA is finally accelerating.
A genuinely bullish report would combine:
A headline beat without those elements may provide only limited reassurance. The decisive disclosures are likely to come on tomorrow’s call rather than in the after-hours EPS number.